IP6K2 (inositol hexakisphosphate kinase 2) functions as a key metabolic enzyme that converts inositol hexakisphosphate (IP6) to diphosphoinositol pentakisphosphate (IP7/5-IP7), a high-energy signaling molecule 12. The enzyme plays crucial roles in cellular energy homeostasis through its interaction with creatine kinase-B, regulating ATP and phosphocreatine production while protecting against oxidative damage 3. IP6K2 is essential for p53-mediated apoptosis, directly binding to p53 and modulating the balance between cell cycle arrest and apoptosis by decreasing expression of pro-arrest targets like p21 1. In cancer contexts, IP6K2 demonstrates complex roles: it promotes glioma progression when upregulated 4, acts as an oncometabolite producer in colorectal cancer by disrupting epithelial barriers through E-cadherin endocytosis 2, yet serves as a tumor suppressor in clear cell renal carcinoma 5. Additionally, IP6K2 influences oncolytic virus therapy resistance 6 and has been associated with Parkinson's disease phenotypes 7. The enzyme's diverse functions highlight its importance in cellular metabolism, apoptosis regulation, and disease pathogenesis across multiple organ systems.